Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140

Benzinga · 1d ago
Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.